Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bacil Pharma Limited has informed BSE that a Board Meeting is scheduled for 22 May 2026 to consider and approve the audited financial results for the quarter and year ended 31 March 2026. The meeting is being held pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This is a standard pre-meeting intimation and does not contain actual financial data or outcomes. The company is listed on BSE with Scrip Code 524516. The notice is signed by Ms. Chaitali Kalpataru Shah, Director & CFO, dated 11 May 2026.
This is a routine procedural filing. The actual impact on the stock will depend on the financial results disclosed after the meeting takes place. No conclusions about company performance can be drawn from this intimation alone.